A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

NCT05193214 | Unknown Phase 2

• 1 other identifier: SSGJ-609-UPS-II-01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The main purpose of this study is to evaluate the efficacy and safety of recombinant anti-PD-1 humanized monoclonal antibody injection (609A) in patients with unresectable or advanced undifferentiated pleomorphic sarcoma

Conditions

Sarcoma, Soft Tissue

Keywords

Sarcoma, Soft Tissue; 609A

Outcome Measures

Primary Outcomes (1)

• ORR,Objective response rate

  CT/MRI examinations were performed every 6 weeks, and the efficacy of anti-tumor treatment was evaluated by RECEIST and iRECEIST standards.

  up to 18 months.

Secondary Outcomes (7)

• AE

  up to 18 months.

• BOR, Best overall response

  up to 18 months.

• DCR, Disease control rate

  up to 18 months.

• DOR, Duration of Response

  up to 18 months.

• TTR, Time to response

  up to 18 months.

Study Arms (1)

609A UPS

EXPERIMENTAL

The 609A single-drug regimen (200mg Q3W) was used to treat unresectable or advanced undifferentiated pleomorphic sarcoma to evaluate the safety and effectiveness of 609A.

Drug: Recombinant anti-PD-1 humanized monoclonal antibody injection

Interventions

Recombinant anti-PD-1 humanized monoclonal antibody injection DRUG

Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.

Also known as: 609A

609A UPS

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A Chinese citizen who understands and is willing to sign an informed consent form (ICF).
• Age ≥18 years old and ≤75 years old, regardless of gender.
• For patients with unresectable or advanced undifferentiated pleomorphic sarcoma confirmed by cytology or histopathology, the subject is willing to provide a sufficient number of tumor tissue sections for pathological type confirmation in the central pathology room.
• At least one anthracycline-containing chemotherapy regimen failed (disease progression or intolerable toxicity).
• There is at least one measurable lesion (see RECIST 1.1 standard for definition).
• The Eastern Cooperative Oncology Group (ECOG) score 0-1 points.
• Life expectancy ≥ 3 months.
• The pregnancy test of female patients with fertility is negative within 3 days before the first administration; any male and female patients with fertility must agree to use medical approval during the entire trial period and within 6 months after the last trial drug is administered. Method of contraception.
• Before 609A starts treatment, it must have sufficient organ functions, including: a) Bone marrow reserve: absolute neutrophil (ANC) ≥1.0×10\^9/L; platelet count ≥90×10\^9/L; Hemoglobin ≥90g/L or ≥5.6mmol/L; b) Total bilirubin≤1.5×ULN, AST and/or ALT≤3×ULN (if abnormal liver function is caused by tumor liver metastasis, then AST and/or ALT≤5×ULN); c) Serum creatinine ≤1.5×ULN or estimated creatinine clearance ≥50mL/min (Cockroft and Gault formula); d) Coagulation test international normalized ratio (INR) ≤2 (except: warfarin anticoagulation The treated patients can receive INR 2 to ≤3), and activated partial thromboplastin time (APTT) ≤1.5×ULN.

You may not qualify if:

• Known to be allergic to protein drugs or recombinant proteins or excipients in 609A pharmaceutical preparations, or have severe allergic reactions after administration of other monoclonal antibodies, or have a history of life-threatening allergies.
• Have received any of the following anti-tumor treatments in the past: a) Have received any anti-tumor treatment within 4 weeks before the first administration, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, hormone therapy (hormone replacement therapy, testosterone or (Except for oral contraceptives), biological therapy and anti-tumor Chinese medicine treatment, etc.; b) Have received immunoagonist treatment within 4 weeks before the first administration; c) Have previously received immunotherapy for T cell co-stimulation or checkpoint approach.
• Have received other drug clinical trial treatment or interventional device clinical trial treatment within 4 weeks before the first administration.
• Underwent major surgery within 21 days before the first administration.
• Live attenuated vaccine was vaccinated within 28 days before the first dose.
• Use of leukocyte-promoting factors such as granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) within 72 hours before the first administration, or 2 weeks before the first administration Have used erythropoietin (EPO) or suspended red blood cell transfusion, or have taken corrective measures such as platelet transfusion within 1 week before the first administration.
• Subjects with central nervous system (CNS) metastasis.
• Suffer from other active malignant tumors within 5 years or at the same time. Excludes cured localized tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, etc.
• A history of any type of primary immunodeficiency, a history of stem cell or organ transplantation.
• Subjects with a history of active autoimmune diseases or autoimmune diseases, including but not limited to immune-related neurological diseases, multiple sclerosis, autoimmune (demyelinating) neuropathy, Green- Barre syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue disease, scleroderma, inflammatory bowel disease including Crohn's disease and ulcerative colitis, hepatitis, toxic epidermal necrolysis ( TEN), Stevens-Johnson syndrome (SJS) or antiphospholipid syndrome.
• Patients who need to be treated with glucocorticoid (\>15mg/d prednisone or equivalent dose of hormone) or other immunosuppressive agents within 14 days before the first administration of the planned trial drug. In the absence of active autoimmune diseases, inhaled or topical glucocorticoids can be used. Hormone replacement therapy doses ≤ 10 mg/d prednisone equivalent are acceptable. Accepts ophthalmology, nasal cavity and intra-articular injection of glucocorticoids.
• There are clinically important cardiovascular and cerebrovascular diseases, including: a) Severe or uncontrollable heart disease that requires treatment, congestive heart failure The New York Heart Association (NYHA) is classified as III or IV, and drugs cannot be controlled. Stable angina pectoris, history of myocardial infarction in the past 6 months, QTc interval of electrocardiogram: male ≥450 milliseconds, female ≥470 milliseconds, severe arrhythmia requiring medical treatment (except for atrial fibrillation or paroxysmal supraventricular tachycardia) . b) Patients with indwelling heart stent within 6 months. c) Insufficient control of hypertension, systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg.
• People with a history of interstitial lung disease, idiopathic pulmonary fibrosis, unresolved active or chronic inflammatory lung disease cannot be included in the group. Subjects who have radiation pneumonia but have recovered can be included in the group;
• People with any of the following infections: a) Active hepatitis B or C. Hepatitis B virus (HBV) carriers without active disease or cured hepatitis C can be included in the group; b) Human immunodeficiency virus (HIV) infection; c) Severe chronic or active infection, requiring systemic antibacterial, antifungal or antibacterial Viral therapy, including active tuberculosis infection, etc.; d) Febrile neutropenia or unexplained single fever\> 38.5°C within 1 week before the first administration of the test drug The fever generated by the tumor can be included in the group).
• Any other serious illnesses (for example: uncontrolled diabetes, active gastric ulcer, uncontrolled epilepsy, cerebrovascular events, gastrointestinal bleeding, coagulopathy with severe symptoms and signs), mental, psychological, Family or geographic conditions, based on the judgment of the investigator, may interfere with trial planning, treatment, and follow-up, or affect the subject's compliance, or put the subject at high risk of treatment-related complications.

Sponsors & Collaborators

• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.: lead

Study Sites (1)

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, 100035, China

Location

MeSH Terms

Conditions

Sarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Xiaohui Niu, Master

  Beijing Jishuitan Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gang Tong, MD

CONTACT

021-60970099; tonggang@3sbio.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 31, 2021
• First Posted: January 14, 2022
• Study Start: January 25, 2022
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2024
• Last Updated: January 14, 2022

Record last verified: 2021-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)